Lipopolysaccharide, lipid A moiety (Lipid A)

Lipid A is the highly conserved, hydrophobic anchor of lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria [PubChem CID 9877306]. It is widely recognized as the primary endotoxic component of LPS, serving as a potent pathogen-associated molecular pattern (PAMP) that triggers the host's innate immune system via the Toll-like receptor 4 (TLR4)/MD-2 complex [PubMed: 10583952]. While this immune activation is crucial for host defense, excessive or systemic exposure to Lipid A can lead to a massive release of pro-inflammatory cytokines, resulting in sepsis, septic shock, and multi-organ failure [NIH/NIGMS]. In clinical practice, Lipid A is a critical target for "last-resort" antibiotics like polymyxins (e.g., Polymyxin B and Colistin), which bind to its negatively charged phosphate groups to disrupt the bacterial cell envelope [StatPearls: Polymyxin B]. Furthermore, research into Lipid A analogs, such as Eritoran, has focused on developing TLR4 antagonists to mitigate the inflammatory damage seen in severe infections [PubMed: 23512121]. Beyond its role as a toxin, modified versions of Lipid A are also utilized as vaccine adjuvants to enhance the immune response to antigens.

Other names

Lipid AEndotoxinLPS lipid ALipid A component of lipopolysaccharide

Polymyxin antibiotics (Polymyxin B and Colistin) bind to the negatively charged phosphate groups of the Lipid A moiety through electrostatic interactions, leading to the displacement of divalent cations and subsequent disruption of the bacterial outer membrane [StatPearls: Polymyxin B]. Additionally, TLR4 antagonists like Eritoran act as structural analogs of Lipid A, competitively binding to the MD-2/TLR4 complex to prevent endotoxin-induced inflammatory signaling [PubMed: 23512121].